Core Insights - The report indicates a significant improvement in the intervention treatment mortality rate for coronary heart disease in Beijing, dropping from 0.10% in 2023 to 0.01% in 2024, marking a historical low [1] - The median D2W time for acute ST-segment elevation myocardial infarction patients has decreased to 57 minutes in 2024, a reduction of 10 minutes from 2022, with 94.9% of cases achieving D2W time under 90 minutes, an increase of 10.8 percentage points from 2022 [1] Group 1 - The Beijing Cardiovascular Internal Medicine Quality Control and Improvement Center analyzed 536 adverse outcome cases in 2024, leading to optimized rescue processes across multiple hospitals, effectively reducing medical risks [2] - The collaborative rescue network in Beijing has been upgraded to cover 65 medical institutions, supported by 11 district-level quality control centers to enhance quality control at the district level [2] - The center aims to achieve homogenization and high-quality development in cardiovascular disease diagnosis and treatment, focusing on specialized training, quality monitoring, and the promotion of information technology tools [2]

在心血管领域的治疗方面，过去临床上很多疗法都是姑息治疗，例如心衰或者严重的瓣膜疾病，很多时候患者来就医时，疾病已经发展到终末期了，没有很 好的治疗方法。 在PCI治疗诊断领域，血管内超声（IVUS）有"黄金眼"之称，对于优化医生在PCI治疗中的评估起到关键作用。借助于人工智能技术的发展，IVUS系统的诊 断精准性得到了进一步的提升。 5月31日，波士顿科学公司用于冠心病诊疗的IVUS诊断系统AVVIGO+正式发布，该系统具备人工智能辅助血管评估功能，可自动实现关键步骤的操作实 施，并提供直观、精确的血管测量数据，显著缩短操作时间。波士顿科学公司数据显示，相比于上一代血管内超声诊断系统，新一代系统可以减少62%的操 作时间。 此外，该系统同时整合了血流储备分数（FFR）和舒张期无充血比率（DFR）测量功能，能帮助评估冠状动脉内部阻塞和狭窄的严重程度，为精准治疗提供 决策依据。 在第十九届东方心脏病学会议OCC 2025（下称：东方会）上，包括全球首款介入主动脉预装干瓣、新一代血管内超声（IVUS）诊断系统、全球首款长效 PCSK9单抗在内的多款创新医疗器械和药品正式发布上市，为心血管疾病诊疗带来创新解决方案。 ...